与ANCA相关的血管炎和肺癌:一种免疫学视角
Longzhao Li1,2, Jun Teng1,2, Na Kou1
1Respiratory Disease Center, Dongzhimen Hospital, Beijing University of Chinese Medicine, No.116 Cuiping West Road, Tongzhou District, 101121, Beijing, China.
Clinical and experimental medicine
|September 4, 2024
概括
反中性细胞质抗体 (ANCA) 相关的血管炎 (AAV) 增加了由于免疫功能障碍和免疫抑制药物导致的肺癌风险. 早期查和仔细的药物管理对于高风险的AAV患者至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
背景情况:
- 反中性细胞质抗体 (ANCA) 相关的血管炎 (AAV) 是一种严重的自身免疫性疾病,影响呼吸系统.
- 癌症发病率,特别是肺癌,在AAV患者中较高,尽管这种联系需要进一步澄清.
- 现有研究强调了将AAV与肺癌联系起来的潜在机制,以及相关的免疫抑制疗法的致癌风险.
研究的目的:
- 审查目前关于AAV患者肺癌风险的文献.
- 探索将AAV与肺癌发展联系在一起的潜在机制.
- 阐明在AAV管理中使用的免疫抑制剂的致癌风险.
主要方法:
- 对AAV和肺癌研究的文献综述.
- 分析潜在的免疫路径 (T细胞衰老,细胞因子表达).
- 评估与免疫抑制药物 (cyclophosphamide,azathioprine,TNF抑制剂) 相关的致癌风险.
主要成果:
- 在AAV和肺癌之间存在相关性,可能由T细胞衰老,损伤和异常IL-6/IL-10表达介导.
- 像环胺 (CYC) 和阿扎西奥普林 (AZA) 这样的免疫抑制剂具有明显的致癌风险,频繁使用CYC会造成肺癌的高风险.
- 虽然TNF抑制剂 (TNFi) 与CYC可能存在风险,但直接证据将它们与肺癌增加联系起来是有限的.
结论:
- 由于疾病特异性免疫失调和免疫抑制治疗的阳性效应,AAV患者面临肺癌的风险增加.
- 合理使用免疫抑制剂,定期CT查和主动肺癌查可以减轻高风险AAV个体的风险.
相关概念视频
Autoimmune Disorders
398
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
398
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493


